MD4531B1 - Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului - Google Patents

Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului Download PDF

Info

Publication number
MD4531B1
MD4531B1 MDA20150104A MD20150104A MD4531B1 MD 4531 B1 MD4531 B1 MD 4531B1 MD A20150104 A MDA20150104 A MD A20150104A MD 20150104 A MD20150104 A MD 20150104A MD 4531 B1 MD4531 B1 MD 4531B1
Authority
MD
Moldova
Prior art keywords
bromodomain inhibitors
compounds
benzimidazolone derivatives
bromodomain
inhibitors
Prior art date
Application number
MDA20150104A
Other languages
English (en)
Russian (ru)
Other versions
MD4531C1 (ro
MD20150104A2 (ro
Inventor
Евангелос АКТОУДИАНАКИС
Грегори ЧИНЬ
Бриттон Кеннет Корки
Цзиньфа Ду
Кристина Элбел
Роберт Х. Цзян
Тецуя Кобаяси
Рубен Мартинес
Сэмюель Е. МЕТОБО
Майкл Миш
Софи Шевик
Дэвид Сперандио
Х Ян
Джефф ЗАБЛОКИ
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of MD20150104A2 publication Critical patent/MD20150104A2/ro
Publication of MD4531B1 publication Critical patent/MD4531B1/ro
Publication of MD4531C1 publication Critical patent/MD4531C1/ro

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epidemiology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Invenţia se referă la compuşi chimici care pot acţiona ca inhibitori sau care în alt mod pot modula activitatea unei proteine conţinând un domeniu bromic, inclusiv a proteinei conţinând domeniul bromic 4 (BRD4), la compoziţii şi formulări ce conţin astfel de compuşi, precum şi la utilizarea unor astfel de compuşi. Compuşii sunt prezentaţi de formula (I)(I),în care semnificaţiile R1a, R1b, R2a, R2b, R3 şi X sunt dezvăluite în descriere şi revendicări.
MDA20150104A 2013-03-28 2014-03-27 Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului MD4531C1 (ro)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361805995P 2013-03-28 2013-03-28
US201361860230P 2013-07-30 2013-07-30
PCT/US2014/032031 WO2014160873A1 (en) 2013-03-28 2014-03-27 Benzimidazolone derivatives as bromodomain inhibitors

Publications (3)

Publication Number Publication Date
MD20150104A2 MD20150104A2 (ro) 2016-02-29
MD4531B1 true MD4531B1 (ro) 2017-11-30
MD4531C1 MD4531C1 (ro) 2018-06-30

Family

ID=50897885

Family Applications (1)

Application Number Title Priority Date Filing Date
MDA20150104A MD4531C1 (ro) 2013-03-28 2014-03-27 Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului

Country Status (35)

Country Link
US (2) US20160031868A1 (ro)
EP (1) EP2978759B1 (ro)
JP (1) JP6339175B2 (ro)
KR (1) KR101847698B1 (ro)
CN (1) CN105102453B (ro)
AP (1) AP2015008741A0 (ro)
AU (1) AU2014241152B2 (ro)
BR (1) BR112015024078A2 (ro)
CA (1) CA2907502C (ro)
CL (1) CL2015002871A1 (ro)
CR (1) CR20150515A (ro)
CY (1) CY1119165T1 (ro)
DK (1) DK2978759T3 (ro)
EA (1) EA029497B1 (ro)
ES (1) ES2626397T3 (ro)
HR (1) HRP20170750T1 (ro)
HU (1) HUE034772T2 (ro)
IL (1) IL241186A0 (ro)
LT (1) LT2978759T (ro)
MD (1) MD4531C1 (ro)
MX (1) MX2015013798A (ro)
MY (1) MY176634A (ro)
NZ (1) NZ711586A (ro)
PE (1) PE20151982A1 (ro)
PH (1) PH12015502246A1 (ro)
PL (1) PL2978759T3 (ro)
PT (1) PT2978759T (ro)
RS (1) RS56050B1 (ro)
SG (1) SG11201507926RA (ro)
SI (1) SI2978759T1 (ro)
SM (1) SMT201700249T1 (ro)
TW (1) TWI530499B (ro)
UY (1) UY35516A (ro)
WO (1) WO2014160873A1 (ro)
ZA (1) ZA201506356B (ro)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009008099A (es) 2007-02-01 2009-12-14 Resverlogix Corp Compuestos para la prevencion y tratamiento de enfermedades cardiovasculares.
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
LT2773354T (lt) 2011-11-01 2019-08-12 Resverlogix Corp. Geriamosios greitai atsipalaiduojančios pakeistų chinozolinų vaisto formos
WO2014080291A2 (en) 2012-11-21 2014-05-30 Rvx Therapeutics Inc. Biaryl derivatives as bromodomain inhibitors
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
WO2014096965A2 (en) 2012-12-21 2014-06-26 Rvx Therapeutics Inc. Novel heterocyclic compounds as bromodomain inhibitors
MX366703B (es) 2013-03-15 2019-07-22 Incyte Holdings Corp Heterociclos tricíclicos como inhibidores de la proteína bet.
WO2015004533A2 (en) 2013-06-21 2015-01-15 Zenith Epigenetics Corp. Novel substituted bicyclic compounds as bromodomain inhibitors
SG11201510409QA (en) 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors
WO2015006193A1 (en) 2013-07-08 2015-01-15 Incyte Corporation Tricyclic heterocycles as bet protein inhibitors
WO2015015318A2 (en) 2013-07-31 2015-02-05 Zenith Epigenetics Corp. Novel quinazolinones as bromodomain inhibitors
US9315501B2 (en) 2013-11-26 2016-04-19 Incyte Corporation Bicyclic heterocycles as BET protein inhibitors
WO2015081203A1 (en) 2013-11-26 2015-06-04 Incyte Corporation Bicyclic heterocycles as bet protein inhibitors
US9309246B2 (en) 2013-12-19 2016-04-12 Incyte Corporation Tricyclic heterocycles as BET protein inhibitors
UA119870C2 (uk) 2014-04-23 2019-08-27 Інсайт Корпорейшн 1H-ПІРОЛО[2,3-c]ПІРИДИН-7(6H)-ОНИ ТА ПІРАЗОЛО[3,4-c]ПІРИДИН-7(6H)-ОНИ ЯК ІНГІБІТОРИ БІЛКІВ BET
ES2855225T3 (es) 2014-09-15 2021-09-23 Incyte Corp Heterociclos tricíclicos para su uso como inhibidores de proteínas BET
JP6820254B2 (ja) * 2014-10-10 2021-01-27 ジェネンテック， インコーポレイテッド 治療用化合物およびその使用
EP3206749B1 (en) 2014-10-14 2021-09-08 The Regents of the University of California The cdk9 and brd4 inhibitors flavopiridol and jq1 to inhibit cartilage inflammation
US10710992B2 (en) 2014-12-01 2020-07-14 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
EP3227280B1 (en) 2014-12-01 2019-04-24 Zenith Epigenetics Ltd. Substituted pyridines as bromodomain inhibitors
JP2017537946A (ja) 2014-12-11 2017-12-21 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての置換複素環
HK1245247A1 (zh) 2014-12-17 2018-08-24 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
JP6903585B2 (ja) 2015-03-13 2021-07-14 レスバーロジックス コーポレイション 補体関連疾患の治療のための組成物および治療方法
GB201504694D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Covalent conjugates
GB201504689D0 (en) 2015-03-19 2015-05-06 Glaxosmithkline Ip Dev Ltd Chemical compounds
WO2016203335A1 (en) 2015-06-18 2016-12-22 Pfizer Inc. Novel pyrido[2,3-b]pyrazinones as bet-family bromodomain inhibitors
TW201722966A (zh) 2015-10-29 2017-07-01 英塞特公司 Bet蛋白質抑制劑之非晶固體形式
WO2017114843A1 (en) 2015-12-29 2017-07-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Xanthine derivative inhibitors of bet proteins
AU2017281286B2 (en) 2016-06-20 2021-05-20 Incyte Corporation Crystalline solid forms of a bet inhibitor
US20180179191A1 (en) * 2016-11-22 2018-06-28 Gilead Sciences, Inc. Synthesis of a compound that modulates the activity of bromodomain-containing proteins
US11180510B2 (en) 2017-11-06 2021-11-23 Centre National De La Recherche Scientifique Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins
WO2019120234A2 (zh) 2017-12-20 2019-06-27 贝达药业股份有限公司 作为溴结构域蛋白质抑制剂的化合物和组合物
JP7394140B2 (ja) * 2019-02-02 2023-12-07 シーエスピーシー ゾンチー ファーマシューティカル テクノロジー（シージアチュアン）カンパニー，リミテッド 標的ユビキチン化分解ｂｒｄ４タンパク質化合物、その調製方法および応用
CN109912584B (zh) * 2019-03-22 2021-08-13 中国药科大学 一种具有抗肿瘤活性的brd4蛋白抑制剂及其制备方法和应用
WO2021065980A1 (ja) 2019-09-30 2021-04-08 協和キリン株式会社 Ｂｅｔ分解剤
US20230183215A1 (en) * 2020-05-21 2023-06-15 Stemsynergy Therapeutics, Inc. Notch Inhibitors and Uses Thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN117821344B (zh) * 2024-03-06 2024-07-26 江苏古道农业科技有限公司 一种草甘膦降解菌及其应用

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5616345A (en) * 1983-12-22 1997-04-01 Elan Corporation Plc Controlled absorption diltiazen formulation for once-daily administration
WO2013024104A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6162804A (en) 1997-09-26 2000-12-19 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US20090176778A1 (en) 2007-08-10 2009-07-09 Franz Ulrich Schmitz Certain nitrogen containing bicyclic chemical entities for treating viral infections
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
GB0919423D0 (en) 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
EP3009427B1 (en) 2011-03-03 2019-12-18 Zalicus Pharmaceuticals Ltd. Benzimidazole inhibitors of the sodium channel
SG11201510409QA (en) * 2013-06-21 2016-01-28 Zenith Epigenetics Corp Novel bicyclic bromodomain inhibitors

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) * 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) * 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5616345A (en) * 1983-12-22 1997-04-01 Elan Corporation Plc Controlled absorption diltiazen formulation for once-daily administration
US5023252A (en) * 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US4992445A (en) * 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US5001139A (en) * 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4902514A (en) * 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
WO2013024104A1 (en) * 2011-08-17 2013-02-21 Glaxosmithkline Llc 4-(8-methoxy-1-((1-methoxypropan-2-yl)-2-(tetrahydro-2h-pyran-4-yl)-1 h-imidazo[4,5-c]quinolin-7-yl)-3,5-dimethylisoxazole and its use as bromodomain inhibitor

Non-Patent Citations (20)

* Cited by examiner, † Cited by third party
Title
Berge S. M. et al., J. Pharma Sci., 66(1), 1-19 (1977) *
BET inhibitor. WikipediA, The Free Encyclopedia. Regăsit în Internet la 2017.04.27, url: https://en.wikipedia.org/wiki/BET_inhibitor *
Brooks, W. H., et al., J. Autoimmun., 34: J207-219 (2010) *
Chung, C. W., et al., J. Med. Chem., 54: 3827-3838 (2011) *
Cohen, I., et al., Genes Cancer, 2: 631-647 (2011) *
Delmore, J. E., et al. Cell, 146, 904-917 (2011) *
Filippakopoulos, P., et al. Cell, 149: 214-231 (2012) *
Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism", Trends Pharmacol. Sci., 5(12):524-527 (1984) *
Iang, Z., et al. Mol. Cell Biol., 28: 967-976 (2008) *
J. Org. Chem. 1995, 60, 3781-3786 *
Loven, J. et al., Cell, 153, 320-334 (2013) *
Muller, S., et al., Expert Rev. Mol. Med., 13: 401-409 (2011) *
Remington: The Sciense and Practice of Pharmacy, R. Hendrickson editor, 21st edition, Lippincott, Williams & Wilkins, Philadelphia, PA, (2005), la pag. 732, Tabelul 38-5 *
Shi Junwei, C.R. Vakoc. The mechanisms behind the therapeutic activity of BET bromodomain inhibition. Mol. Cell. 2014 June 5; 54(5): 728-736. DOI: 10.1016/j.molvel.2014.05.016. Regăsit în Internet la 2017.09.07, url: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4236231/ *
Shirodkar, A.V. and Marsden, P.A., Curr. Opin. Cardiol., 26: 209-215 (2011) *
Urano, E., et al., FEBS Lett., 582: 405-408 (2008) *
Villeneuve, L.M., etal., Clin. Exp. Pharmacol. Physiol., 38: 401-409 (2011) *
Wierda, R. J., et al., J. Cell Mol. Med., 14: 1225-1240 (2010) *
Wu, S.I., Chiang, C.M. J. Biol. Chem., 282: 13141-13145 (2007) *
Zhou, M., et al., J. Virol., 83: 1036-1044 (2009) *

Also Published As

Publication number Publication date
HK1220692A1 (en) 2017-05-12
AP2015008741A0 (en) 2015-09-30
MY176634A (en) 2020-08-19
HUE034772T2 (en) 2018-02-28
US9255089B2 (en) 2016-02-09
ZA201506356B (en) 2017-08-30
PH12015502246A1 (en) 2016-02-01
SMT201700249T1 (it) 2017-07-18
HRP20170750T1 (hr) 2017-07-28
WO2014160873A1 (en) 2014-10-02
RS56050B1 (sr) 2017-09-29
IL241186A0 (en) 2015-11-30
CN105102453A (zh) 2015-11-25
EA201591455A1 (ru) 2016-01-29
KR101847698B1 (ko) 2018-04-10
UY35516A (es) 2014-09-30
TW201504233A (zh) 2015-02-01
PE20151982A1 (es) 2016-01-28
US20140296246A1 (en) 2014-10-02
LT2978759T (lt) 2017-05-25
KR20150135476A (ko) 2015-12-02
AU2014241152A1 (en) 2015-09-17
CL2015002871A1 (es) 2016-05-13
EP2978759B1 (en) 2017-03-15
CY1119165T1 (el) 2018-02-14
DK2978759T3 (da) 2017-06-19
PL2978759T3 (pl) 2017-08-31
MD4531C1 (ro) 2018-06-30
CN105102453B (zh) 2018-04-06
MD20150104A2 (ro) 2016-02-29
PT2978759T (pt) 2017-05-31
EP2978759A1 (en) 2016-02-03
BR112015024078A2 (pt) 2017-07-18
JP6339175B2 (ja) 2018-06-06
US20160031868A1 (en) 2016-02-04
JP2016515584A (ja) 2016-05-30
SI2978759T1 (sl) 2017-05-31
AU2014241152B2 (en) 2016-11-03
CR20150515A (es) 2015-12-01
SG11201507926RA (en) 2015-10-29
EA029497B1 (ru) 2018-04-30
ES2626397T3 (es) 2017-07-24
NZ711586A (en) 2016-09-30
TWI530499B (zh) 2016-04-21
CA2907502C (en) 2018-02-27
MX2015013798A (es) 2016-02-16
CA2907502A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
MD4531B1 (ro) Derivaţi ai benzimidazolonei în calitate de inhibitori ai bromodomeniului
PH12015502534A1 (en) Benzimidazole derivatives as bromodomain inhibitors
MA32508B1 (fr) Composes organiques
PH12015501868A1 (en) Inhibitors of histone demethylases
JO3007B1 (ar) مركبات و تركيبات كمثبطات كيناز بروتين
IN2015MN00405A (ro)
MX2012000709A (es) Inhibidores de pirrolopiridina de cinasas.
UA116467C2 (uk) Модулятори p2x7
MX2016008110A (es) Derivados de pirazol como inhibidores de la cinasa de cremallera de leucina dual (dlk) y usos de los mismos.
MX356342B (es) Agente de control de endoparásitos y método para usarlo.
NZ729618A (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
CR20140135A (es) Nuevos derivados de aril-quinolina
CR20160171A (es) NUEVO OCTAHIDRO-CICLOBUTA[1,2-c; 3,4-c] DIPIRROL-2-ILO
PH12019500839A1 (en) Therapeutic compounds and methods of use thereof
MX390051B (es) Antagonistas de ep4.
MX2018001317A (es) Inhibidores del virus sincitial respiratorio.
MX2015016332A (es) Inhibidores de alk biciclicos fusionados.
UA115583C2 (uk) Азетидинілоксифенілпіролідинові сполуки
NZ719465A (en) Quinoline derivatives as bromodomain inhibitors
MX2016006509A (es) Compuestos triciclicos de piperidina.
TN2019000038A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
MX2015010790A (es) Derivados de anilina sustituidos con n-heteroarilo como antivirales de vhc.
UA110131C2 (ru) ПРОИЗВОДНЫЕ ТИЕНО[2,3-d]ПИРИМИДИНА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ АРИТМИИ
PH12015500292A1 (en) 3,4-disubstituted oxazolidinone derivatives and their use as inhibitors of the calcium activated potassium channel
UA111315C2 (uk) Похідні бензімідазолону як інгібітори бромодомену

Legal Events

Date Code Title Description
FG4A Patent for invention issued
KA4A Patent for invention lapsed due to non-payment of fees (with right of restoration)
MM4A Patent for invention definitely lapsed due to non-payment of fees